- Stocks
- Healthcare
- NASDAQ: INVA

Price (delayed)

$11.18

Market cap

$761.65M

P/E Ratio

3.64

Dividend/share

N/A

EPS

$3.07

Enterprise value

$1.01B

Innoviva, Inc. is a healthcare focused asset management company. The Company intends to participate in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva operates in the United States.

The stock's price to earnings (P/E) is 39% less than its 5-year quarterly average of 6.0 and 39% less than its last 4 quarters average of 6.0

Innoviva's quick ratio has plunged by 95% YoY but it has increased by 15% from the previous quarter

The equity has increased by 36% year-on-year but it has declined by 12% since the previous quarter

The debt has grown by 37% YoY

The company's EPS fell by 29% QoQ and by 5% YoY

What are the main financial stats of INVA

Market
Valuations
Earnings

Shares outstanding

68.13M

Market cap

$761.65M

Enterprise value

$1.01B

Price to earnings (P/E)

3.64

Price to book (P/B)

1.38

Price to sales (P/S)

2.35

EV/EBIT

3.41

EV/EBITDA

3.2

EV/Sales

3.05

Revenue

$331.34M

EBIT

$296.4M

EBITDA

$315.91M

Free cash flow

$201.66M

Per share
Balance sheet
Liquidity

EPS

$3.07

Free cash flow per share

$2.9

Book value per share

$8.11

Revenue per share

$4.76

TBVPS

$13.67

Total assets

$1.23B

Total liabilities

$665.71M

Debt

$540.37M

Equity

$565.79M

Working capital

$308.54M

Debt to equity

0.96

Current ratio

3.29

Quick ratio

2.63

Net debt/EBITDA

0.79

Margins
Efficiency
Dividend

EBITDA margin

95.3%

Gross margin

95.8%

Net margin

64.6%

Operating margin

141.9%

Return on assets

17.8%

Return on equity

43.2%

Return on invested capital

26%

Return on capital employed

27%

Return on sales

89.5%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Innoviva stock price performed over time

Intraday

-2.44%

1 week

3.61%

1 month

-9.98%

1 year

-41.98%

YTD

-15.62%

QTD

-15.62%

How have Innoviva's revenue and profit performed over time

Revenue

$331.34M

Gross profit

$317.55M

Operating income

$470.32M

Net income

$213.92M

Gross margin

95.8%

Net margin

64.6%

The operating margin has increased by 50% YoY but it has decreased by 4.1% from the previous quarter

INVA's operating income is up by 27% YoY but it is down by 15% QoQ

INVA's net income is down by 27% since the previous quarter and by 20% year-on-year

The gross profit is down by 19% YoY and by 14% from the previous quarter

What is Innoviva's growth rate over time

What is Innoviva stock price valuation

P/E

3.64

P/B

1.38

P/S

2.35

EV/EBIT

3.41

EV/EBITDA

3.2

EV/Sales

3.05

The stock's price to earnings (P/E) is 39% less than its 5-year quarterly average of 6.0 and 39% less than its last 4 quarters average of 6.0

The company's EPS fell by 29% QoQ and by 5% YoY

The P/B is 65% below the 5-year quarterly average of 3.9 and 40% below the last 4 quarters average of 2.3

The equity has increased by 36% year-on-year but it has declined by 12% since the previous quarter

The P/S is 45% lower than the 5-year quarterly average of 4.3 and 13% lower than the last 4 quarters average of 2.7

The revenue has contracted by 15% YoY and by 11% from the previous quarter

How efficient is Innoviva business performance

INVA's ROA is down by 38% YoY and by 32% from the previous quarter

INVA's return on equity is down by 32% since the previous quarter and by 28% year-on-year

The return on invested capital has declined by 22% since the previous quarter and by 18% year-on-year

The company's return on sales fell by 13% QoQ and by 2.9% YoY

What is INVA's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for INVA.

How did Innoviva financials performed over time

The total assets is 85% greater than the total liabilities

Innoviva's quick ratio has plunged by 95% YoY but it has increased by 15% from the previous quarter

The company's current ratio has shrunk by 94% YoY but it rose by 19% QoQ

The debt is 4.5% less than the equity

The debt has grown by 37% YoY

The equity has increased by 36% year-on-year but it has declined by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.